KR20200110995A - Preparation method of fermented beans with antiobesity effect using sedum sarmentosum bunge and astragali radix - Google Patents
Preparation method of fermented beans with antiobesity effect using sedum sarmentosum bunge and astragali radix Download PDFInfo
- Publication number
- KR20200110995A KR20200110995A KR1020190030662A KR20190030662A KR20200110995A KR 20200110995 A KR20200110995 A KR 20200110995A KR 1020190030662 A KR1020190030662 A KR 1020190030662A KR 20190030662 A KR20190030662 A KR 20190030662A KR 20200110995 A KR20200110995 A KR 20200110995A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- kodium
- weight
- oxol
- Prior art date
Links
- 241000612118 Samolus valerandi Species 0.000 title abstract description 6
- 241000304432 Sedum sarmentosum Species 0.000 title abstract description 5
- 230000000694 effects Effects 0.000 title description 21
- 230000003579 anti-obesity Effects 0.000 title description 10
- 244000046052 Phaseolus vulgaris Species 0.000 title description 7
- 235000010627 Phaseolus vulgaris Nutrition 0.000 title description 7
- 238000002360 preparation method Methods 0.000 title description 7
- -1 stragali Species 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 244000068988 Glycine max Species 0.000 claims abstract description 36
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 36
- 239000000284 extract Substances 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 208000008589 Obesity Diseases 0.000 claims abstract description 5
- 235000020824 obesity Nutrition 0.000 claims abstract description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 26
- 235000019206 astragalus extract Nutrition 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 4
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims description 4
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 4
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 4
- 229940094952 green tea extract Drugs 0.000 claims description 4
- 235000020688 green tea extract Nutrition 0.000 claims description 4
- 229960000448 lactic acid Drugs 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 238000000855 fermentation Methods 0.000 abstract description 4
- 230000004151 fermentation Effects 0.000 abstract description 4
- 238000010025 steaming Methods 0.000 abstract description 4
- 229940116248 astragalus propinquus root extract Drugs 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 description 18
- 230000001953 sensory effect Effects 0.000 description 13
- 235000009200 high fat diet Nutrition 0.000 description 12
- 235000019640 taste Nutrition 0.000 description 12
- 241000220286 Sedum Species 0.000 description 10
- 235000006533 astragalus Nutrition 0.000 description 8
- 230000004584 weight gain Effects 0.000 description 8
- 235000019786 weight gain Nutrition 0.000 description 8
- 241001061264 Astragalus Species 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 210000004233 talus Anatomy 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000037356 lipid metabolism Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 102000023984 PPAR alpha Human genes 0.000 description 3
- 108010028924 PPAR alpha Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000282819 Giraffa Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 239000011449 brick Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000003687 soy isoflavones Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- HAIWUXASLYEWLM-AZEWMMITSA-N Sedoheptulose Natural products OC[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@](O)(CO)O1 HAIWUXASLYEWLM-AZEWMMITSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- HSNZZMHEPUFJNZ-SHUUEZRQSA-N sedoheptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-SHUUEZRQSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A23L11/09—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Abstract
Description
본 발명은 코듐옥돌나물 추출물 및 황기 추출물을 이용하여 증자한 콩을 유효성분으로 하는, 비만 억제 효능을 갖는 발효콩 함유 조성물을 제조하는 방법에 대한 것이다.The present invention relates to a method for preparing a composition containing fermented soybeans having an anti-obesity effect, using as an active ingredient, soybeans grown using a cordum oxol sprout extract and Astragalus extract.
돌나물(Sedum sarmentosum Bunge)은 돌나물과에 속하는 오래살이풀로 전국의 어디에서나 자생하고 주로 양지 바른 돌 사이나 위에서 많이 자라고 있는데, 이와 같이 돌 위에서도 잘 자라는 끈질긴 생명력을 가진 특성 때문에 돌나물이라는 이름이 붙여졌다. 별명인 석채(石蔡)도 이러한 의미에서 붙여진 이름인데, 이외에도 돈나물 또는 전채라고도 불리며 유사종으로는 기린초와 가는 기린초가 있다. Sedum sarmentosum Bunge (Sedum sarmentosum Bunge) is a long-lived plant belonging to the sedum family. It grows naturally anywhere in the country and mainly grows between and on sunny stones.Sedum sarmentosum Bunge is named because of its persistent vitality that grows well on stones . The nickname Seokchae (石蔡) is also a name given in this sense, and it is also called a pork sprout or appetizer, and similar species include giraffe and fine giraffe.
돌나물에는 세도헵툴로스, 수크로스, 프룩토스 등의 당질과 비타민C와 칼슘의 함량이 높으며, 항고혈압, 간염바이러스 억제 및 간보호 효과, 간암세포의 성장억제 및 알코올 대사 촉진효과, 활성산소 소거활성 및 멜라닌생성 저해 효과, 폐경으로 인한 장애를 감소시키기 위하여 에스트로겐 장기간 복용에 의한 부작용 감소, 항암 등의 효능이 있는 것으로 알려져 있다.Sedum sprouts contain high sugars such as sedoheptulose, sucrose, fructose, vitamin C, and calcium, and have antihypertension, hepatitis virus inhibition and hepatoprotective effects, growth inhibition of liver cancer cells and promotion of alcohol metabolism, free radical scavenging activity. And it is known to have an effect of inhibiting melanogenesis, reducing side effects by long-term use of estrogen in order to reduce disorders due to menopause, and anti-cancer effects.
돌나물은 건강식품 및 의약품 소재로서 활용 가능성이 매우 높은 특용식물로서 대량 재배가 필요한 실정이나 기존의 돌나물은 마디에 뿌리가 내려 옆으로 뻗아나가는 반포복성이며, 대량 생육에 한계가 있다는 단점이 있었는데, 신규 작물인 코듐옥돌나물은 직립형 생육 돌나물로서 기존 돌나물에 비해 생육속도가 빠르고 병충해에 강하며 잎이 넓고 두꺼운 돌나물이다. Sedum sedum is a special plant with high potential for use as a health food and pharmaceutical material, and requires mass cultivation.However, the existing sedum sprouts are semi-crawling, with roots descending on nodes and extending to the side, and there was a disadvantage in that mass growth was limited. The new crop, kodium oleum, is an upright growing sedum, which has a faster growth rate than the existing sedum and is resistant to pests and diseases, and is a sedum with wide and thick leaves.
황기는 황기(Astragali Radix)는 황기(Astragalus membranaceus Bunge, 콩과 Leguminosae)의 뿌리로서 그대로 또는 주피를 제거하여 사용하는 보기제(補氣劑)로 발한 억제, 강장, 강심, 체력증강, 피로회복 등의 목적으로 한의학에서 다용되는 약물임. 주요 기능성분으로는 cycloartane-type sapnin, isoflavonoid 및 다당체가 보고되어져 있다.Astragali Radix is the root of Astragalus membranaceus Bunge (bean and Leguminosae). It is a drug that is widely used in oriental medicine for the purpose of Cycloartane-type sapnin, isoflavonoid, and polysaccharide have been reported as major functional components.
황기의 사포닌은 Con A로 활성화된 T lymphocytes에서 면역세포 활성화에 필요한 cytokine 생산을 촉진시키며, 항염증작용으로 대장세포 섬유화를 억제하고, 황기의 물 추출물은 손상된 정맥내피 세포의 정상화 및 dextran sulfate sodium로 유도한 대장염의 NF-kB 활성화를 억제하며, flavonoid계 화합물은 dendritic cell의 염증관련 cytokine류의 분비를 억제하는 작용 등이 알려져 있다. Astragalus saponin promotes the production of cytokine required for immune cell activation in T lymphocytes activated by Con A, inhibits colon cell fibrosis with anti-inflammatory action, and water extract of Astragalus spines normalizes damaged venous endothelial cells and uses dextran sulfate sodium. It is known to inhibit the activation of NF-kB in induced colitis, and flavonoid compounds inhibit the secretion of inflammation-related cytokines in dendritic cells.
또한 황기의 주성분인 Astragalus polysaccharide의 항당뇨, 항산화 효과 등이 밝혀져 있으며, 특히 Astragalus polysaccharide는 비만형 당뇨병 동물모델에서 인슐린저항성 개선 혈당강화효과 및 아데노신 모노 포스페이트(adenosine mono phosphate, AMP)-활성화 프로테인 키나아제(activated protein kinase) (AMPK)의 증가 및 항비만 효과가 있음이 밝혀져 있다.In addition, the antidiabetic and antioxidant effects of Astragalus polysaccharide, the main component of Astragalus, have been found. In particular, Astragalus polysaccharide improves insulin resistance in an obese diabetic animal model, enhances blood sugar, and adenosine monophosphate (AMP)-activated protein kinase. It has been shown to increase protein kinase) (AMPK) and have anti-obesity effects.
콩의 이소플라본은 지질대사의 이상과 관련된 심혈관 질환과 고지혈증을 개선시키는 것으로 알려져 있으며 콩의 이소플라본의 주된 성분인 제니스타인(genistein)은 실험동물과 사람에서 심장혈관질환과 고지혈증을 개선시켰다.제니스타인이 풍부한 식사를 처방했을 때 폐경 전 정상 콜레스테롤 혈증(normocholesterolemia) 여성의 혈장 지질 수준이 감소하였다고 알려져 있다. 제니스타인의 주요한 효과는 HMG-CoA reductase와 Low density lipoprotein receptor와 같은 콜레스테롤대사에 관여하는 유전자 발현의 변화의 의해 매개된다. PPAR α는 지질대사와 관련된 많은 유전자의 전사를 조절하는 요인이며 PPAR α의 활성은 지방산의 베타 산화를 증가시키고 세포상 또는 순환하는 지질 수준을 감소시킨다. 제니스타인은 PPAR α의 활성을 증가시키는 것으로 보고된 바 있다.Soy isoflavones are known to improve cardiovascular disease and hyperlipidemia related to abnormal lipid metabolism, and genistein, a major component of soy isoflavones, improved cardiovascular disease and hyperlipidemia in experimental animals and humans. It is known that pre-menopausal women with normocholesterolemia decreased plasma lipid levels when a diet rich in others was prescribed. The main effects of Zenistine are mediated by changes in the expression of genes involved in cholesterol metabolism such as HMG-CoA reductase and low density lipoprotein receptor. PPAR α is a factor that regulates the transcription of many genes involved in lipid metabolism, and the activity of PPAR α increases the beta oxidation of fatty acids and decreases the level of cellular or circulating lipids. Zenistine has been reported to increase the activity of PPAR α.
한편, 한국을 대표하는 전통식품 중 청국장과 된장은 콩을 주원료로 한 발효식품으로 단백질, 식이섬유, 기능성분 등을 골고루 섭취 할 수 있는 대표적인 건강식이지만 세계보건기구 일일 나트륨의 권고상한치 2,000 mg(소금으로 약 5 g)의 주요 급원으로 2배 수준에 달하며, 장류식품의 대표적인 된장의 경우, 성인 1인당 섭취량은 약 27.0 g/day로 그에 따른 염분 섭취량은 약 3.0 g/day 이상으로 1일 섭취 소금양의 많은 부분에 기여하고, 제조공정 및 시간이 긴 단점을 가지고 있다.On the other hand, among Korea's representative traditional foods, Cheonggukjang and Doenjang are fermented foods made with soybeans as the main ingredients, and are representative healthy foods that can evenly consume protein, dietary fiber, and functional ingredients, but the recommended upper limit of sodium per day is 2,000 mg (salt). As a major source of about 5 g), it reaches twice the level, and in the case of a typical soybean paste of soybean paste, the intake per adult is about 27.0 g/day, and the corresponding salt intake is about 3.0 g/day or more. It contributes to a large part of the quantity, and has the disadvantage of a long manufacturing process and time.
또한 냄새나 식감에 대한 거부감 때문에 섭취를 꺼리는 경우가 많으며, 특히 유아나 혹은 청소년들은 중장년층에 비해 청국장을 접할 기회가 적어 익숙하지 않은 식품으로 여겨지고 있으며, 1인 가구의 증가, 가정 내 직접 조리 수요가 줄고, 전통 장류를 이용하는 요리보다는 간편식을 활용하는 세대가 늘어나면서 장류의 시장규모 및 섭취량은 감소하고 있는 추세에 있다.In addition, in many cases they are reluctant to eat because of the rejection of the smell or texture. In particular, infants and adolescents are considered unfamiliar food because they have fewer opportunities to encounter cheonggukjang compared to the middle-aged, increasing the number of single-person households, and demand for direct cooking in the home. As the number of generations who use convenience food rather than dishes using traditional sauces is increasing, the market size and intake of sauces are on the decline.
상기 서술하였듯이 고영양, 고기능성 제품인 장류는 고 나트륨 함유, 특유의 냄새와 식감에 대한 거부감, 편의성 부족, 제조공정의 장시간 소요 등의 문제점을 가지고 있으므로 이를 해결하기 위해서는 웰빙 트렌드에 따른 제품의 변화(고기능성), 섭취에 대한 거부감 완화(고기호성), 소포장 등의 편의성 강화 및 활용도를 높인 장류 형태의 다양화, 즉, 특유의 냄새와 조리의 불편함 때문에 쉽게 먹기 힘든 소비행태를 반영한 제품으로 가공방식 변화가 요구되고 있다.As described above, paste, which is a highly nutritious and highly functional product, has problems such as high sodium content, a sense of rejection of its characteristic odor and texture, lack of convenience, and a long period of the manufacturing process. To solve this problem, the product changes according to the well-being trend ( High functionality), alleviation of refusal to eat (meat taste), and diversification of the form of paste with enhanced convenience and increased utilization of small packages, that is, processed into a product that reflects the consumption behavior that is difficult to eat due to its characteristic odor and inconvenience of cooking. There is a demand for a method change.
본 발명은 코듐옥돌나물 및 황기 추출물이 추가된 수중에서 증자된 콩을 발효시켜 얻어진 발효콩을 유효성분으로 하는 항비만 활성의 식품조성물을 제공하는 것을 목적으로 한다.It is an object of the present invention to provide a food composition having anti-obesity activity, comprising fermented soybeans obtained by fermenting soybeans grown in water to which kodium oxol sprouts and Astragalus extracts are added as an active ingredient.
본 발명은 코듐옥돌나물 추출물과 황기 추출물을 함유하는 물에 침지하여 콩을 증자시킨 후 증자된 콩에 유산균을 접종하여 발효시켜 얻어진 발효콩 분말을 유효성분으로 포함하는 비만 예방 식품조성물을 제공한다. The present invention provides a food composition for preventing obesity, comprising fermented soybean powder obtained by fermentation by inoculating lactic acid bacteria in the increased soybean by immersing it in water containing a kodium oxol sprout extract and astragalus extract and astragalus extract as an active ingredient.
상기 증자된 콩은 코듐옥돌나물 추출물 1 내지 9 중량%, 황기 추출물 1 내지 9 중량% 및 물 82 내지 98중량%의 혼합에 콩을 침지하여 증자시켜 얻어지는 것이 바람직하다. The steamed soybean is preferably obtained by immersing the beans in a mixture of 1 to 9% by weight of kodium oxol sprout extract, 1 to 9% by weight of Astragalus extract, and 82 to 98% by weight of water.
상기 식품 조성물은 발효콩 분말에 코듐옥돌나물 추출물, 녹차추출물, 가르시니아캄보지아 추출물, L-카르니틴, 프락토올리고당 및 유산균으로 이루어진 그룹 중에서 선택되는 어느 하나 이상을 추가로 포함할 수 있다. The food composition may further include any one or more selected from the group consisting of fermented soybean powder, kodium oxol sprout extract, green tea extract, garcinia cambogia extract, L-carnitine, fructooligosaccharide, and lactic acid bacteria.
코듐옥돌나물은 기존 돌나물을 개량하여 재배한 신품종 작물로서 기존 돌나물에 비해 키가 크게 자라고 잎이 보다 넓고 두꺼운 특성을 지닌 다년생 식물로 직립형으로 성장하는 작물이다(대한민국 특허출원 제10-2018-0113031호). 코듐옥돌나물은 일반 돌나물에 비해 면역능력에 표지가 되는 산화질소(NO, Nitric Oxide) 생성능이 유의적으로 높음이 확인되었다(건조된 코듐옥돌나물 1g당 15mg의 NO 검출됨).Kodium Okdolnamul is a new crop grown by improving the existing sedum, and is a perennial plant that grows taller than the existing sedum and has wider and thicker leaves, and is a crop that grows upright (Korean Patent Application No. 10-2018-0113031 ). It was confirmed that kodium oxol sprouts had a significantly higher ability to produce nitric oxide (NO), which is a marker for immunity, compared to general sedum sprouts (15 mg of NO was detected per 1 g of dried kodium oxol sprouts).
또한, 본 발명의 가장 바람직한 항비만 활성의 식품조성물은 발효콩 분말 85 내지 95중량%와 코듐옥돌나물 추출액(40브릭스) 5 내지 15중량%의 중량비로 혼합한 조성물이고, 보다 더 바람직하게는 발효콩 분말 90중량%에 코듐옥돌나물 추출액(40브릭스) 10중량%인 것이 항비만 활성이 높다.In addition, the most preferred anti-obesity activity food composition of the present invention is a composition obtained by mixing fermented soybean powder in a weight ratio of 85 to 95% by weight and 5 to 15% by weight of a kodium oxol sprout extract (40 brix), and more preferably fermentation The anti-obesity activity is high when the soybean powder is 90% by weight and 10% by weight of the extract (40 brix) of kodium oxol sprouts.
본 발명에 따르면, 코듐옥돌나물 추출물과 황기 추출물을 콩의 증자 전에 첨가함으로써 콩을 불리는 과정과 증자 중에 유용물질이 콩의 내부에 침투하여 유용물질의 함유량을 증가시킴과 동시에 콩의 비린내를 저감시키는 효과를 거둘 수 있으며, 상기 유용물질이 콩이 발효 시에 생물전환이 용이하여 항비만 활성이 향상되는 효과를 얻을 수 있다.According to the present invention, by adding Kodium oxol sprout extract and Astragalus extract before steaming soybeans, useful substances penetrate into the inside of soybeans during the so-called process and steaming, thereby increasing the content of useful substances and reducing the fishy smell of beans. It is possible to achieve an effect, and the useful material can be easily bioconverted during fermentation of soybeans, thereby improving anti-obesity activity.
본 발명을 실시예를 통하여 상세히 설명한다. 단, 하기의 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기의 실시예에 의해 한정되는 것은 아니다. The present invention will be described in detail through examples. However, the following examples are merely illustrative of the present invention, and the contents of the present invention are not limited by the following examples.
실시예1: 코듐옥돌나물 추출물과 황기 추출물의 제조Example 1: Preparation of Kodium oxol sprout extract and Astragalus extract
1) 코듐옥돌나물 추출물의 제조1) Preparation of the extract of kodium oxoleum
건조시킨 코듐옥돌나물 2.5kg에 25L의 물을 가수하여 80℃에서 6시간 추출하여 여과, 농축시켜 40브릭스 추출물을 제조한다. 구체적인 추출공정은 하기와 같다(표1):25 L of water was added to 2.5 kg of dried cordum oxol sprouts, extracted at 80° C. for 6 hours, filtered, and concentrated to prepare a 40 Bricks extract. The specific extraction process is as follows (Table 1):
2) 황기 추출물의 제조2) Preparation of Astragalus extract
건조시킨 황기 2.5kg에 25L의 물을 가수하여 80℃에서 6시간 추출하여 여과, 농축시켜 40브릭스 추출물을 제조한다. 구체적인 추출공정은 하기와 같다(표2):25L of water was added to 2.5kg of dried Astragalus, extracted for 6 hours at 80°C, filtered, and concentrated to prepare 40 Bricks extract. The specific extraction process is as follows (Table 2):
실시예 2 : 본 발명의 콩의 증자 및 발효콩의 제조Example 2: Preparation of increase of soybean and fermented soybean of the present invention
원료 콩을 1.5 kg씩 계량하여 3개의 시료를 준비하여 각각 3회 세척한 후 이물질 및 물기를 제거한 뒤, ①코듐옥돌나물추출물(40 Brix) 10중량%, ②황기추출물(40 Brix) 10중량%, ③코듐옥돌나물추출물(40 Brix) 5중량%+황기추출물 5중량%(40 Brix)를 각각 물에 첨가하여 2kg을 만들어 이에 준비한 원료 콩 1.5kg씩 12-15시간동안 침지시켜 불린 후 면포에 싸서 3-4시간 증자하였다. 증자된 콩에 Bacillus subtilis, Aspergillus oryzae를 각각 접종하여 24시간 발효시켜 발효콩을 제조하였다. 구체적인 공정은 하기와 같다(표3):After weighing 1.5 kg of raw material, prepare 3 samples, wash each 3 times, remove foreign substances and water, ① 10% by weight of Kodium oxol sprout extract (40 Brix), ② 10% by weight of Astragalus extract (40 Brix) , ③ 5% by weight of Kodium oxol sprout extract (40 Brix) + 5% by weight of Astragalus kelp extract (40 Brix) are added to water to make 2 kg, and 1.5 kg of the prepared raw beans are immersed for 12-15 hours. It was wrapped and increased for 3-4 hours. Bacillus subtilis and Aspergillus oryzae were respectively inoculated into the increased soybeans and fermented for 24 hours to prepare fermented soybeans. The specific process is as follows (Table 3):
실시예 3: 본 발명의 발효콩 조성물의 제조Example 3: Preparation of fermented soybean composition of the present invention
하기 표와 같은 조성물 1 내지 4를 제조하되, 각 조성물의 원료인 발효콩은 증자에 첨가된 유용성분이 ①코듐옥돌나물추출물(40 Brix) 10중량%, ②황기추출물(40 Brix) 10중량%, 및 ③코듐옥돌나물추출물(40 Brix) 5중량% 및 황기추출물 5중량%(40 Brix)인 경우로 나누어 준비하였다(표 4). Compositions 1 to 4 as shown in the following table are prepared, but the useful ingredients added to the fermented soybeans, the raw material of each composition, are ① kodium oxol sprout extract (40 Brix) 10% by weight, ② Astragalus extract (40 Brix) 10% by weight, And ③ was prepared by dividing the case of 5% by weight of kodium oxol sprout extract (40 Brix) and 5% by weight of Astragalus extract (40 Brix) (Table 4).
즉, 조성물 1 ①은 코듐옥돌나물추출물(40 Brix) 10중량%에서 증자하여 발효시킨 콩, 조성물 1 ②는 황기추출물(40 Brix) 10중량%에서 증자하여 발효시킨 콩, 조성물 1 ③은 코듐옥돌나물추출물(40 Brix) 5중량% 및 황기추출물 5중량%(40 Brix)에서 증자하여 발효시킨 콩 100%로 구성된 것을 의미한다.In other words, Composition 1 ① is beans grown and fermented from 10% by weight of kodium oxol sprout extract (40 Brix), Composition 1 ② is beans grown and fermented from 10% by weight of Astragalus extract (40 Brix), and Composition 1 ③ is Kodium Odole. It means consisting of 100% soybeans fermented by steaming in 5% by weight of herb extract (40 Brix) and 5% by weight of Astragalus extract (40 Brix).
L-carnitine +프락토올리고당Composition 2 + Kodium oxol sprout (freeze-dried powder) + green tea extract + garcinia cambogia extract +
L-carnitine + fructooligosaccharide
실험예 1: 본 발명의 발효콩 조성물의 관능평가Experimental Example 1: Sensory evaluation of the fermented soybean composition of the present invention
1) 조성물 1 ①, 조성물 1 ② 및 조성물 1 ③의 관능평가 1) Sensory evaluation of composition 1 ①, composition 1 ② and composition 1 ③
관능평가는 20대 남녀 5명과 30대 5명, 40대 이상 5명을 대상으로 색, 향, 맛 및 전체적인 기호도의 4가지 평가항목을 기초로 하여 대조구 1종과 조성물 1 3종에 대하여 5점 척도법(1 : 매우나쁘다, 2 : 나쁘다, 3 : 보통이다, 4 : 좋다, 5 : 매우 좋다)을 이용하여 표시하도록 하였으며, 결과는 각 평가항목별 합의 평균을 나타낸다.The sensory evaluation was based on 4 evaluation items of color, aroma, taste and overall acceptability for 5 men and women in their 20s, 5 people in their 30s, and 5 people in their 40s or older, and 5 points for 1 control and 3 composition 1 The scale method (1: very bad, 2: bad, 3: moderate, 4: good, 5: very good) was used to indicate, and the result represents the average of the sum of each evaluation item.
대조구 1종과 조성물 1 3종을 제조하여 패널 15명을 대상으로 관능평가를 실시한 결과 대조구에 비해 조성물 1 3종이 전반적으로 기호도가 높게 나타났으며, 그 중에서도 맛과 전체적인 기호도에서 조성물 1 ③이 가장 높게 나타났다(표 5).As a result of conducting sensory evaluation for 15 panelists by preparing 1 control and 3 compositions 1, 3 compositions 1 showed higher overall acceptability than the control, and among them, Composition 1 ③ was the most in taste and overall acceptability. It was high (Table 5).
2) 조성물 2 ①, 조성물 2 ②, 및 조성물 2 ③의 관능평가2) Sensory evaluation of composition 2 ①, composition 2 ②, and composition 2 ③
하기와 같은 조성물을 배합하여 상기 조성물 1의 관능평가와 같은 방법으로 실시하였다(표 6). 관능평가 결과 조성물 1 ③와 동일하게 조성물 2 ③이 가장 기호도가 높게 나타났다.The following composition was blended and carried out in the same manner as for the sensory evaluation of Composition 1 (Table 6). As a result of sensory evaluation, composition 2 ③ showed the highest degree of acceptability, similar to composition 1 ③.
3) 조성물 3의 관능평가3) Sensory evaluation of composition 3
조성물 3은 조성물 2의 각 조성에 하기 표와 같은 추가 유용성분을 배합하여 12가지 배합으로 제조하였다(표 7). 상기 조성물 1에서와 같은 방법으로 관능평가하였다. 그 결과, 조성물 2 대조구에 비해 조성물 2 ③과 배합한 조성물 3들의 맛, 향, 전체적인 기호도 모두 좋았다(색은 유사함). 녹차추출물의 경우 쓴맛이 매우 강하여 10% 이상 첨가하는 것은 맛과 전체적인 기호도에 문제가 있을 것으로 보이고, 가르시니아 캄보지아추출물 및 L-Carnitine은 맛에 영향력을 많이 주지 않았다. 프락토올리고당의 첨가량이 증가할수록 맛과 전체적인 기호도는 상승하였다. 코듐옥돌나물추출물 동결건조분말 첨가 시 특유의 맛과 향이 강하게 느껴져 5%를 초과하는 것은 맛과 전체적인 기호도에 문제가 있을 것으로 보였다. Composition 3 was prepared in 12 formulations by blending additional useful ingredients as shown in the following table to each composition of Composition 2 (Table 7). Sensory evaluation was performed in the same manner as in Composition 1. As a result, compared to the composition 2 control group, the taste, aroma, and overall taste of the composition 2 ③ and composition 3 were all good (the color is similar). In the case of green tea extract, the bitter taste is very strong, so adding more than 10% seems to have problems in taste and overall acceptability, and garcinia cambogia extract and L-Carnitine did not have much influence on taste. As the amount of fructooligosaccharide increased, taste and overall acceptability increased. When the freeze-dried powder of the kodium oxol sprout extract was added, the characteristic taste and aroma were strongly felt, and the taste and overall acceptability in excess of 5% seemed to be problematic.
최종 관능평가 결과 조성물 3 ⑥, ⑩이 가장 기호도가 높은 것으로 나타났다.As a result of the final sensory evaluation, the composition 3 ⑥ and ⑩ showed the highest preference.
4) 조성물 4.: 제조방법은 조성물 3과 같음4) Composition 4.: The preparation method is the same as that of Composition 3.
상기 최종 관능평가 결과 기호도가 가장 높은 조성물 3 ⑥, ⑩에 유산균혼합분말(8종)을 첨가(1포 7 g 당 147억)하여 하기 표와 같이 배합하여 관능평가를 실시하였다. 그 결과 맛에는 차이가 나타나지 않았다. As a result of the final sensory evaluation, a mixture of lactic acid bacteria powder (8 types) was added to the compositions 3 ⑥ and ⑩ with the highest acceptability (14.7 billion KRW per 7 g of one bag), and the mixture was mixed as shown in the following table to perform sensory evaluation. As a result, there was no difference in taste.
실험예 2: 본 발명의 조성물의 기호도 평가Experimental Example 2: Evaluation of the preference of the composition of the present invention
20대 남녀 10명과 30대 5명, 40대 이상 10명을 대상으로 색, 향, 맛 및 전체적인 기호도의 4가지 평가항목을 기초로 하여 하기 표 9와 같은 조성의 대조구 1종과 조성물 4 종에 대하여 5점 척도법(1 : 매우나쁘다, 2 : 나쁘다, 3 : 보통이다, 4 : 좋다, 5 : 매우 좋다)을 이용하여 표시하도록 하였으며, 결과는 각 평가항목별 합의 평균을 나타내었다.Based on the four evaluation items of color, aroma, taste, and overall acceptability for 10 men and women in their 20s, 5 in their 30s, and 10 people in their 40s or older, one control and 4 compositions of the composition shown in Table 9 below The five-point scale (1: very bad, 2: bad, 3: moderate, 4: good, 5: very good) was used to display the results, and the result was the average of the sum of each evaluation item.
대조구 1종과 조성물 4종을 제조하여 패널 25명을 대상으로 관능평가를 실시한 결과 색을 제외한 모든 항목에서 대조구에 비해 조성물 4종의 기호도가 높게 나타났다(표 10).One control group and 4 compositions were prepared, and sensory evaluation was conducted on 25 panelists. As a result, in all items except color, the preference of the 4 compositions was higher than that of the control group (Table 10).
실험예 3: 발효콩 및 발효콩 조성물의 항비만 효과Experimental Example 3: Anti-obesity effect of fermented soybean and fermented soybean composition
실시예 3에서 제조한 최종 조성물 4종에 대한 체중감소 효과와 지질개선 활성을 고지방식 마우스를 사용하여 조사하였다. 이 때 대조군은 코듐옥돌나물과 황기추출물을 첨가하고 발효시킨 발효콩 100%를 사용하였다. The weight loss effect and lipid improvement activity of the 4 final compositions prepared in Example 3 were investigated using high fat diet mice. In this case, 100% fermented soybeans fermented after adding kodium oxol sprout and Astragalus extract were used as a control group.
1) 동물실험 1) Animal testing
실험에 사용된 쥐는 평균체중 18.4±1.6 g인 4주령 ICR 암컷 생쥐로서 일반식이로 1주일간 적응시킨 후 일반식이군과 고지방식이군으로 나누어 한 그룹당 4마리로 구성하였다.The mice used in the experiment were 4-week-old ICR female mice with an average weight of 18.4±1.6 g, and after being acclimated to a regular diet for 1 week, the mice were divided into the regular diet group and the high fat diet group, and consisted of 4 mice per group.
실험군은 일반식이 섭취군(NFD), 고지방식이 섭취군(HFD), 고지방식이 섭취군에서 대조군(HFD-C), 조성물 1 투여군(HFD-C1), 조성물 2 투여군(HFD-C2), 조성물 3 투여군(HFD-C3) 및 조성물 4 투여군(HFD-C4) 등 7종으로 나누었다(표 11).The experimental group was the general diet intake group (NFD), the high fat diet intake group (HFD), the high fat diet intake group to the control group (HFD-C), the composition 1 administration group (HFD-C1), the composition 2 administration group (HFD-C2), It was divided into 7 types, including the composition 3 administration group (HFD-C3) and the composition 4 administration group (HFD-C4) (Table 11).
시료를 투여하는 HFD-C, -C1, -C2, -C3 및 -C4 군은 고지방식이를 섭취시킴과 동시에 48시간 간격으로 열수추출물을 60 mg/kg, 총 35번 복강 투여하였고, 일반식이 섭취군과 고지방식이 섭취군에서는 시료 투여군과 동일한 횟수로 생리식염수를 복강 주사하였으며, 실험기간동안 이틀에 한 번씩 체중을 측정하였다.HFD-C, -C1, -C2, -C3, and -C4 groups administered the sample consumed a high fat diet and at the same time administered hot water extract 60 mg/kg at 48-hour intervals, intraperitoneally administered a total of 35 times. In the intake group and the high-fat diet intake group, physiological saline was injected intraperitoneally at the same number of times as the sample administration group, and the body weight was measured every two days during the experiment.
사육실 온도는 22±2℃, 습도는 55±5%로 유지하였고, 명암은 12시간 간격으로 조절하였으며, 물과 식이는 제한 없이 공급하였다. 일반식이와 고지방식이의 구성성분은 하기 표12와 같다.The temperature of the breeding room was maintained at 22±2℃ and the humidity was 55±5%, and the contrast was adjusted at 12 hour intervals, and water and diet were supplied without limitation. The components of the general diet and high fat diet are shown in Table 12 below.
2) 항비만 효과2) anti-obesity effect
① 체중증가량 ① Weight gain
실험동물을 10주간 조성물 열수추출물 60 mg/kg을 2일 간격으로 35회 복강 투여하였고, 6주 및 10주 후 체중을 측정하였음. 체중 증가량은 [10주 체중-6주 체중]으로 계산하였고, 체중증가율은 [(10주 체중-6주 체중)/6주 체중]×100으로 계산하였다.Experimental animals were administered intraperitoneally with 60 mg/kg of the hot water extract of the composition for 10 weeks at intervals of 2 days, and body weight was measured after 6 and 10 weeks. The weight gain was calculated as [10 weeks body weight-6 weeks body weight], and the weight gain rate was calculated as [(10 weeks body weight-6 weeks body weight)/6 weeks body weight]×100.
비만유도기간 6주 후 각 그룹간의 체중 증가를 조사한 결과 일반식이 투여군(NFD)에 비해 고지방식 투여군(HFD) 모두에서 유의하게 체중이 증가하여 비만이 잘 유도되었음이 확인되었다.As a result of investigating the weight gain between each group 6 weeks after the obesity induction period, it was confirmed that the weight gain was significantly increased in both the high fat diet group (HFD) compared to the general diet group (NFD), and thus obesity was well induced.
10.69 g의 체중이 증가한 고지방식 투여군(HFD)에 비해 고지방식 대조군 투여군(HFD-C) 6.75 g, 고지방식 조성물 1, 2, 3, 4 투여군은 체중 증가가 각각 2.24 g, 0.65 g, 1.23 g, 1.42 g으로 나타나 코듐옥돌나물의 첨가량이 많을수록 체중 증가는 감소하였다(HFD-C2). Compared to the high fat diet group (HFD), which gained 10.69 g of body weight, the high fat diet control group (HFD-C) 6.75 g, the high fat diet composition 1, 2, 3, and 4 dose groups showed weight gain of 2.24 g, 0.65 g, and 1.23 g, respectively. , 1.42 g, the weight gain decreased as the amount of kodium oxol sprout increased (HFD-C2).
또한 체중증가율도 HFD-C2에서 2.69%로 가장 낮게 나타나 항비만 효과가 가장 우수하였다.In addition, the weight gain was the lowest at 2.69% in HFD-C2, showing the best anti-obesity effect.
② 지질대사 개선 효과 ② Lipid metabolism improvement effect
혈청 내 지질 농도를 알아보기 위해 혈청 중성지질(triglyceride, TC), 총 콜레스테롤(total cholesterol, TC) 및 고밀도 지단백 콜레스테롤(high-densty lipoprotein cholesterol, HDL-C) 농도는 혈청 생화학적 측정기계(DRI-CHEM 3500i, FUJI Film, Japan)를 이용하여 비색측정하였음. 한편 TG, TC, HDL-C 수치를 이용하여 HDL-C/TC비 (HDL-C/TC ratio, HTR) 및 동맥경화지수(atherogenic index, AI)를 계산하였다. To determine the lipid concentration in the serum, serum triglyceride (TC), total cholesterol (TC), and high-densty lipoprotein cholesterol (HDL-C) concentrations were measured using a serum biochemical measuring instrument (DRI- Colorimetric measurement was made using CHEM 3500i, FUJI Film, Japan). Meanwhile, HDL-C/TC ratio (HDL-C/TC ratio, HTR) and atherosclerosis index (AI) were calculated using TG, TC, and HDL-C values.
HTR=HDL-C의 농도 / TC의 농도 HTR = concentration of HDL-C / concentration of TC
AI=[TC의 농도-(HDL-C의 농도)] / HDL-C의 농도 AI=[concentration of TC-(concentration of HDL-C)] / concentration of HDL-C
혈청 총 콜레스테롤(TC) 농도는 고지방식 HFD로 (184.1±3.7 mg/dl)에 비해 조성물 투여군 1, 2, 3, 4에서 각각 163.6, 160.5, 162.6, 161.0 mg/dl으로 낮았고, HDL-콜레스테롤(HDL-C)은 높게 검출되었다. 중성지질(TG) 농도는 고지방식 HFD군 (201.5±17.2 mg/dl)에 비해 조성물 투여군 모두에서 10% 이상 낮게 검출되어 지질대사 개선효과가 확인되었다. HTR은 NFD보다 조성물 투여군 모두에서 높게 나타났고, 동맥경화지수도 10% 이상 낮게 나타났는데, 코듐옥돌나물 첨가량이 많을수록 지질대사 개선효과가 가장 높게 나타났다(HFD-C2)(표 14).Serum total cholesterol (TC) concentration was 163.6, 160.5, 162.6, 161.0 mg/dl in the composition administration groups 1, 2, 3, 4, respectively, compared to the high fat diet HFD (184.1±3.7 mg/dl), and HDL-cholesterol ( HDL-C) was highly detected. The triglyceride (TG) concentration was detected lower than 10% in all of the composition administration groups compared to the high fat diet HFD group (201.5±17.2 mg/dl), confirming the lipid metabolism improvement effect. HTR was higher in all groups administered with the composition than in NFD, and the arteriosclerosis index was also lowered by more than 10%, and the higher the amount of kodium oxol sprout was, the higher the lipid metabolism improvement effect was (HFD-C2) (Table 14).
Claims (3)
A food composition for preventing obesity containing fermented soybeans obtained by fermenting the increased soybeans after increasing soybeans by immersing in the extract of kodium oxol sprout and Astragalus extract.
A food composition characterized in that it is obtained by immersing soybeans in a mixture of 1 to 9% by weight of kodium oxol sprout extract, 1 to 9% by weight of Astragalus extract, and 82 to 98% by weight of water.
The composition of claim 1 is a food composition further comprising any one or more selected from the group consisting of kodium oxol sprout extract, green tea extract, garcinia cambogia extract, L-carnitine, fructooligosaccharide and lactic acid bacteria.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190030662A KR102250815B1 (en) | 2019-03-18 | 2019-03-18 | Preparation method of fermented beans with antiobesity effect using sedum sarmentosum bunge and astragali radix |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190030662A KR102250815B1 (en) | 2019-03-18 | 2019-03-18 | Preparation method of fermented beans with antiobesity effect using sedum sarmentosum bunge and astragali radix |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200110995A true KR20200110995A (en) | 2020-09-28 |
KR102250815B1 KR102250815B1 (en) | 2021-05-11 |
Family
ID=72801226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190030662A KR102250815B1 (en) | 2019-03-18 | 2019-03-18 | Preparation method of fermented beans with antiobesity effect using sedum sarmentosum bunge and astragali radix |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102250815B1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040095949A (en) * | 2003-04-29 | 2004-11-16 | (주)바이오뉴트리젠 | Composition comprising herb with usage to prevent obeseness |
KR20110097188A (en) * | 2010-02-25 | 2011-08-31 | 김순동 | Health functional food composition consisting of astragalus membranaceus extracts, red yeast rice extracts and liquid red yeast rice |
KR101847601B1 (en) * | 2017-11-20 | 2018-04-11 | 주식회사 홈스푸드 | Method for preparing a fermented soybean, the fermented soybean prepared by the method, and the food composition comprising the fermented soybean |
KR20180113031A (en) | 2017-04-05 | 2018-10-15 | 엘지전자 주식회사 | A laundry treating apparatus |
-
2019
- 2019-03-18 KR KR1020190030662A patent/KR102250815B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040095949A (en) * | 2003-04-29 | 2004-11-16 | (주)바이오뉴트리젠 | Composition comprising herb with usage to prevent obeseness |
KR20110097188A (en) * | 2010-02-25 | 2011-08-31 | 김순동 | Health functional food composition consisting of astragalus membranaceus extracts, red yeast rice extracts and liquid red yeast rice |
KR20180113031A (en) | 2017-04-05 | 2018-10-15 | 엘지전자 주식회사 | A laundry treating apparatus |
KR101847601B1 (en) * | 2017-11-20 | 2018-04-11 | 주식회사 홈스푸드 | Method for preparing a fermented soybean, the fermented soybean prepared by the method, and the food composition comprising the fermented soybean |
Non-Patent Citations (1)
Title |
---|
돌나물의 건강 기능성 구명과 유전자원 보존 및 산업적 이용기술 개발. 과제 최종보고서. 농림수산식품부. 2008년 1부.* * |
Also Published As
Publication number | Publication date |
---|---|
KR102250815B1 (en) | 2021-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101619271B (en) | Traditional Chinese medicine combination spice for cigarette as well as preparation method and application thereof | |
CN106615431B (en) | Jerusalem artichoke tea tablets and preparation method thereof | |
KR100862305B1 (en) | Functional soybean paste containing extract of medicinal crops and manufacturing process thereof | |
CN106389788A (en) | Medicine extract for strengthening anti-virus capability and immune function of livestock, preparation, and preparation method | |
KR101464716B1 (en) | Health supplementation food using winter worm summer grass as main ingredient and its manufacturing method | |
CN108618128A (en) | Adjust the composition and its preparation method and application of immunity | |
KR102250815B1 (en) | Preparation method of fermented beans with antiobesity effect using sedum sarmentosum bunge and astragali radix | |
KR102168192B1 (en) | Healthful mixed tea development using fermented herbs, fruits and shiitake | |
KR101787337B1 (en) | the fermented samultang extracting method with the function of both anti-oxidation and immunity and the samultang extract using thereof | |
CN111264877A (en) | Preparation method of medicinal and edible high-fiber functional food | |
KR100894537B1 (en) | A manufacturing method of jelly using a bokbunja | |
KR20130130131A (en) | Vinegar composition fermented with black garlic and preparation method thereof | |
CN103815080B (en) | Tartary buckwheat instant tea and preparation method thereof | |
CN105535035A (en) | Inonotus obliquus fermentation culture composition and preparation method thereof | |
CN101744240A (en) | Ginkgo leaf nutritious and health-care fine dried noodles and preparation method thereof | |
KR102422425B1 (en) | A method of manufactureing root vegetable soybean paste with excellent antioxident activity and taste | |
KR20190077802A (en) | Method for producing glutinous rice cake using persimmon, grain and medicinal plant | |
KR20170120053A (en) | the fermented samultang extracting method with the function of both anti-oxidation and immunity and the samultang extract using thereof | |
KR101375347B1 (en) | The method for manufacuting red ginseng drink with medicinal herb, and the red ginseng drink made by the method | |
KR101909936B1 (en) | Food composition for enhancing function of immunity comprising fermented extract from material natural food by lactic acid bacteria and preparation method thereof | |
KR101722584B1 (en) | Butchu fermentated extract using Lactic acid bacteria sp. and anti-diabetic composition comprising the same | |
KR101402600B1 (en) | Instant noodle manufacturing methods | |
KR20100116919A (en) | Compositions comprising extract from codonopsis lanceolata for preventing or treating obesity, hyperlipidemia or fatty liver | |
CN111743189A (en) | Preparation method of herbal plant solid spice for cigarettes | |
KR20170055356A (en) | soybean meat containing large quantity of conjugated linoleic acid and isoflavone and manufacturing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |